June 11, 2009 (FinancialWire) — Ingen Technologies, Inc. (OTC: IGNT) has received an increase in Oxyview orders and telephone orders from COPD patients and new distributor inquiries from the advertisement in the COPD Digest.

In March-2009 Ingen signed an insertion order with COPD Digest to run a national advertisement for the new Oxyview. COPD Digest is published by the COPD Foundation, with the support of — and contributions from — organizations representing the entire COPD community. Chronic Obstructive Pulmonary Disease affects over 600 million people worldwide. Oxyview provides these patients with the ability to assure oxygen flow and equipment function.

“Since the ad was issued last week with over 160,000 circulations, there has been an increase with on-line orders through our website and PayPal, as well as telephone orders. The patients and new potential distributors are very pleased with the new Oxyview product,” stated Chris Wirth, Chief Operations officer.

Oxyview is a proprietary medical device with U.S.-issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease in the United States, according to the World Health Organization.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.